Drug intelligence / Profile preview

A27.15

Development stage: Phase 1
Lead developer: National Cancer Institute
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

A27.15 is a murine IgG1 monoclonal antibody that targets the human transferrin receptor (TfR). By binding to the transferrin receptor, A27.15 blocks the binding of transferrin, potentially inhibiting iron uptake in cells expressing this receptor. This mechanism may be relevant for therapeutic strategies targeting cancer or other diseases where modulation of iron metabolism or TfR function is beneficial[1][4].

Other names: monoclonal antibody A27.15

Targets

TFRC (Transferrin Receptor)

Beyond the preview

Go deeper on A27.15.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on A27.15.

Explore the full profile